NEWS - Sep 20, 2023 Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder Read more
NEWS - Aug 23, 2023 Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder Read more
NEWS - Aug 8, 2023 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Read more
NEWS - Aug 1, 2023 Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 Read more
NEWS - Jun 8, 2023 Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference Read more
NEWS - Jun 2, 2023 Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference Read more
NEWS - May 24, 2023 Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting Read more
NEWS - May 11, 2023 Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results Read more
NEWS - May 8, 2023 Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023 Read more
NEWS - Mar 23, 2023 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results Read more
